<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04173039</url>
  </required_header>
  <id_info>
    <org_study_id>18071A0003</org_study_id>
    <nct_id>NCT04173039</nct_id>
  </id_info>
  <brief_title>Anti-Carbamylated Protein Antibodies in Psoriatic Arthritis</brief_title>
  <acronym>CARPAPA</acronym>
  <official_title>Diagnostic Value of Antibodies Against Carbamylated Proteins in Psoriatic Arthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association pour la Recherche Clinique et Immunologique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association pour la Recherche Clinique et Immunologique</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anti-carbamylated protein (anti-CarP) antibodies are present in approximately one-fourth of
      the patients who are seronegative for both rheumatoid factor and anti-citrullinated protein
      antibody and who may therefore have psoriatic arthritis. The investigators hypothesized that
      detection of anti-CarP antibodies in serum may be useful for diagnosis of psoriatic
      arthritis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 29, 2018</start_date>
  <completion_date type="Actual">April 24, 2019</completion_date>
  <primary_completion_date type="Actual">April 24, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity of anti-carbamylated protein antibodies for the diagnosis of psoriatic arthritis in the psoriatic population</measure>
    <time_frame>Anti-CarP antibodies will be assessed in the sera collected at the recruitment visit</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Psoriasis</condition>
  <condition>Arthritis, Psoriatic</condition>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with psoriasis and without psoriatic arthritis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients with psoriatic arthritis and with personal or familial psoriasis.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Serum anti-CarP antibodies detection</intervention_name>
    <description>Serum anti-CarP antibodies detection using an enzyme-linked immunosorbent assay (ELISA) from Inova Diagnostics.</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &quot;Controls&quot; : Patients with a psoriasis confirmed by a dermatologist and with absence
             of psoriatic arthritis confirmed by a rheumatologist.

          -  &quot;Cases&quot; : Patients with psoriatic arthritis fulfilling the classification criteria for
             psoriatic arthritis (CASPAR), with a diagnosis confirmed by a rheumatologist and
             associated with personal or familial psoriasis.

        Exclusion Criteria:

          -  &quot;Controls&quot;: Presence of any chronic rheumatic inflammatory disease such as psoriatic
             arthritis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre-BÃ©nite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>November 20, 2019</study_first_submitted>
  <study_first_submitted_qc>November 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2019</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

